Bergen, Norway

Rolf Reed

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Biophausia Ab (Publ). Active years: 2001.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2001

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Rolf Reed: Innovator in Anti-Cancer Agent Delivery

Introduction

Rolf Reed is a notable inventor based in Bergen, Norway. He has made significant contributions to the field of cancer treatment through his innovative work on drug delivery systems. His research focuses on enhancing the effectiveness of anti-cancer agents, particularly in solid tumors.

Latest Patents

Rolf Reed holds a patent for an invention titled "Enhanced anti-cancer agent delivery to solid tumors by primer compounds." This patent describes primer compositions that facilitate the delivery of anti-cancer agents to solid tumors in mammals, including humans. The primer comprises a pharmaceutically acceptable agent that increases the intracellular levels of cyclic adenosine monophosphate (cAMP) in normal connective tissue cells within solid tumors. By locally administering the primer to the tumor area, the interstitial pressure is lowered, improving the delivery of anti-cancer agents.

Career Highlights

Rolf Reed has dedicated his career to advancing cancer treatment methodologies. His work has led to the development of innovative solutions that aim to improve patient outcomes. He is associated with Biophausia AB, a company focused on biopharmaceutical advancements.

Collaborations

Rolf Reed has collaborated with notable colleagues, including Kristofer Rubin and Mats Sjoquist. These partnerships have contributed to the success of his research and the development of effective cancer treatment strategies.

Conclusion

Rolf Reed's contributions to the field of anti-cancer agent delivery represent a significant advancement in cancer treatment. His innovative approaches and collaborations continue to pave the way for improved therapeutic options for patients.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…